On ECHEMI
Home > Drugs > Beijing Hanmi Pharmaceutical Co., Ltd.
Beijing Hanmi Pharmaceutical Co., Ltd.
  • Founded in:

    1996-03-27
  • Country:

    China China
  • Address:

    No. 10, Tianzhu West Road, Area A, Tianzhu Airport Industrial Zone, Shunyi District, Beijing
  • Tax NO.:

    91110113600048921K
  • Registered Funds:

    630 million yuan
  • Website:

  • Email:

Related Drugs
Amibutrol oral solution
This product is a compound preparation, containing 1.5 mg of ambroxol hydrochloride and 1 μg of clenbuterol hydrochloride per ml.
Name Description Content CAS NO. Registered Holders
Ambroxol hydrochloride

Mucolytics can increase the secretion of respiratory mucosal serous glands, reduce mucous gland secretion, reduce sputum viscosity, promote the secretion of pulmonary surfactant, increase bronchial ciliary movement, and make sputum easier to cough up.

More

Mucolytics can increase the secretion of respiratory mucosal serous glands, reduce mucous gland secretion, reduce sputum viscosity, promote the secretion of pulmonary surfactant, increase bronchial ciliary movement, and make sputum easier to cough up.

1.5mg 23828-92-4 38
Clenbuterol hydrochloride

Selective beta-receptor agonists relax bronchial smooth muscles, enhance ciliary movement, dissolve mucus, and promote sputum discharge

More

Selective beta-receptor agonists relax bronchial smooth muscles, enhance ciliary movement, dissolve mucus, and promote sputum discharge

1μg 21898-19-1 14
Amibutrol Tablets
This product is a compound preparation, its components are ambroxol hydrochloride and clenbuterol hydrochloride.
Name Description Content CAS NO. Registered Holders
Ambroxol hydrochloride

Mucolytics can increase the secretion of respiratory mucosal serous glands, reduce mucous gland secretion, reduce sputum viscosity, promote the secretion of pulmonary surfactant, increase bronchial ciliary movement, and make sputum easier to cough up.

More

Mucolytics can increase the secretion of respiratory mucosal serous glands, reduce mucous gland secretion, reduce sputum viscosity, promote the secretion of pulmonary surfactant, increase bronchial ciliary movement, and make sputum easier to cough up.

23828-92-4 38
Clenbuterol hydrochloride

Selective beta-receptor agonists relax bronchial smooth muscles, enhance ciliary movement, dissolve mucus, and promote sputum discharge

More

Selective beta-receptor agonists relax bronchial smooth muscles, enhance ciliary movement, dissolve mucus, and promote sputum discharge

21898-19-1 14
Lactulose oral solution
This product contains 667 mg of the main ingredient lactulose per milliliter
Name Description Content CAS NO. Registered Holders
Lactulose

Lactulose is not absorbed in the small intestine, and only a small part of the acidic metabolites produced by its decomposition in the colon are absorbed. This leads to increased osmotic pressure in the intestinal cavity, retention of water and electrolytes, increased intestinal volume, mechanical stimulation to the intestinal wall, and chemical stimulation from the acidic metabolites, resulting in laxative effects.

More

Lactulose is not absorbed in the small intestine, and only a small part of the acidic metabolites produced by its decomposition in the colon are absorbed. This leads to increased osmotic pressure in the intestinal cavity, retention of water and electrolytes, increased intestinal volume, mechanical stimulation to the intestinal wall, and chemical stimulation from the acidic metabolites, resulting in laxative effects.

667mg 4618-18-2 20
Finasteride Tablets
The main ingredient of this product is finasteride. Molecular weight: C23H36N2O2
Name Description Content CAS NO. Registered Holders
Finasteride

This product belongs to the 4-nitrogen steroid hormone compound, which is a specific type II 5α-reductase competitive inhibitor. It inhibits the conversion of peripheral testosterone into dihydrotestosterone and reduces the level of dihydrotestosterone in the blood, prostate, skin and other tissues. The growth, development and benign hyperplasia of the prostate depend on dihydrotestosterone. Finasteride inhibits prostate hyperplasia and improves the related clinical symptoms of benign prostatic hyperplasia by reducing the level of dihydrotestosterone in the blood and prostate tissue.

More

This product belongs to the 4-nitrogen steroid hormone compound, which is a specific type II 5α-reductase competitive inhibitor. It inhibits the conversion of peripheral testosterone into dihydrotestosterone and reduces the level of dihydrotestosterone in the blood, prostate, skin and other tissues. The growth, development and benign hyperplasia of the prostate depend on dihydrotestosterone. Finasteride inhibits prostate hyperplasia and improves the related clinical symptoms of benign prostatic hyperplasia by reducing the level of dihydrotestosterone in the blood and prostate tissue.

98319-26-7 50
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.